OXiGENE Announces Clinical Data From FACT Study to be Presented at the 14th International Thyroid Congress

SOUTH SAN FRANCISCO, Calif., June 24, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases, announced today that data from
its clinical trials of ZYBRESTAT and chemotherapy in patients with anaplastic
thyroid cancer (ATC), will be presented at the upcoming 14th International
Thyroid Congress in Paris, France, on September 12, 2010.  OXiGENE will release
a summary of results immediately after they are presented. 

ZYBRESTAT Presentation Details:

Oral Presentation Title: RANDOMIZED PHASE 2/3 TRIAL OF A TUMOR VASCULAR
DISRUPTING AGENT FOSBRETABULIN TROMETHAMINE (CA4P) WITH CARBOPLATIN (C), AND
PACLITAXEL (P) IN ANAPLASTIC THYROID CANCER (ATC): INTERIM SAFETY AND EFFICACY
RESULTS OF THE FACT TRIAL 

Presenter: Rossella Elisei, M.D.

Session Title: Prospective trials in refractory thyroid cancers

Date: Sunday 12 Sept.

Time of session: 14:45 - 16:15

Location: Room Bordeaux - level 3

About ZYBRESTAT (fosbretabulin)

ZYBRESTAT is being evaluated in a Phase 2 study of patients with non-squamous
non-small cell lung cancer and other clinical trials.  OXiGENE believes that
ZYBRESTAT is poised to become an important product in a novel class of
small-molecule drug candidates called vascular disrupting agents.  Through
interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT
selectively targets and collapses tumor vasculature, thereby depriving the
tumor of oxygen and causing death of tumor cells.  In clinical trials in solid
tumors, ZYBRESTAT has demonstrated potent and selective activity against tumor
vasculature, as well as clinical activity against anaplastic thyroid cancer,
ovarian cancer and various other solid tumors. 

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases. The Company's major focus is
developing vascular disrupting agents that selectively disrupt abnormal blood
vessels associated with solid tumor progression and visual impairment.  OXiGENE
is dedicated to leveraging its intellectual property and therapeutic
development expertise to bring life-extending and life-enhancing medicines to
patients. 

The OXiGENE, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=4969 

Safe Harbor Statement

This news release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995.  Any or all of the
forward-looking statements in this press release, which include projected study
outcomes, emerging oncology treatments and the expected conclusion of ongoing
or initiation of new clinical studies may turn out to be wrong. Forward-looking
statements can be affected by inaccurate assumptions OXiGENE might make or by
known or unknown risks and uncertainties, including, but not limited to, the
outcome of clinical studies and the availability of additional financing to
continue development of ZYBRESTAT.  Additional information concerning factors
that could cause actual results to materially differ from those in the
forward-looking statements is contained in OXiGENE's reports to the Securities
and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and
8-K. However, OXiGENE undertakes no obligation to publicly update
forward-looking statements, whether because of new information, future events
or otherwise.  Please refer to our Annual Report on Form 10-K for the fiscal
year ended December 31, 2009. 

CONTACT:  OXiGENE, Inc.
          Investor and Media Contact:
          Michelle Edwards, Investor Relations
          medwards@oxigene.com
          650-635-7006